GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (FRA:APS) » Definitions » Net Income Including Noncontrolling Interests

Asarina Pharma AB (FRA:APS) Net Income Including Noncontrolling Interests : €-0.78 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Asarina Pharma AB's Net Income Including Noncontrolling Interests for the three months ended in Jun. 2023 was €0.00 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.78 Mil.

Asarina Pharma AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Asarina Pharma AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Net Income Including Noncontrolling Interests Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -4.29 -6.78 -7.40 -3.08 -1.21

Asarina Pharma AB Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.39 -0.39 - -

Asarina Pharma AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asarina Pharma AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB (FRA:APS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (FRA:APS) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XSAT:ALTE OSTO:CYXO OSTO:DIABIO OSTO:REDW OSTO:PHARM OSTO:AMNI XSAT:PHAL OSTO:LIDDS OSTO:SPAGO OSTO:CLINE B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ASAP:Sweden
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Website
https://www.asarinapharma.com
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (FRA:APS) Headlines

No Headlines